^
Association details:
| Biomarker: | HER-2 amplification |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Aidixi (disitamab vedotin) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
588P - First real-world study with HER2 ADC in treating HER2-altered non-small cell lung cancer
Published date:
11/27/2023
Excerpt:
A total of 22 patients with HER2 alterations were enrolled, including 15 with HER2 mutations, 5 with HER2 amplifications, and 2 with both. The overall objective response rate (ORR) was 45.5% (10/22), disease control rate (DCR) was 90.9% (20/22), and median progression-free survival (mPFS) stood at 7.5 months (95% CI 6.6-8.4 months). 95.5% of patients (21/22) underwent combination therapy, yielding an ORR of 47.6% (10/21)....The mPFS was notably prolonged in HER2-amplified patients and anti-HER2 naïve patients....For HER2-altered NSCLC patients, RC48 combined therapies are applicable treatment options, particularly with platinum agents.
